Keywords

CF, cystic fibrosis, drug approvals, FDA, HIV, migraine, nausea and vomiting of pregnancy, new drugs, NVP, opioid withdrawal, plaque psoriasis

Authors

1. Mospan, Cortney PharmD, BCACP, BCGP
2. Mospan, Geoffrey PharmD, BCPS
3. Byland, Emily
4. Whitaker, William Blake
5. Xiong, Linda
6. Dunlap, Jordan
7. Canupp, Katherine

Abstract

Abstract: In 2018, the FDA approved several new drugs for use in primary care. This article highlights the following new drugs: bictegravir, emtricitabine, and tenofovir alafenamide (Biktarvy); doxylamine succinate and pyridoxine hydrochloride (Bonjesta); erenumab-aooe (Aimovig); lofexidine hydrochloride (Lucemyra); tezacaftor and ivacaftor (Symdeko); and tildrakizumab-asmn (Ilumya).